logo
NASA's Spacecraft Reveals Io To Be A Hellishly Active Volcanic Moon

NASA's Spacecraft Reveals Io To Be A Hellishly Active Volcanic Moon

Forbes07-05-2025
Io, one of the four Galilean moons of Jupiter, as seen by the Galileo probe, circa 1997. (Photo by ... More Space Frontiers/) Getty Images
New data from NASA's Juno $1.2 billion spacecraft now in orbit around Jupiter reveals that the massive planet's Galilean moon of Io has recently undergone the most massive eruptions ever observed in our solar system. Only about the size of our own moon, Io is much hotter and more volcanically active than the Juno team could have ever imagined.
There's nothing in our solar system that we've seen that has so many volcanoes all going off at the same time, continuously, hundreds of them, Scott Bolton, principal investigator of NASA's Juno at the Southwest Research Institute in San Antonio, tells me at the European Geosciences Union General Assembly in Vienna. Io has volcanoes all over the place, he says.
Juno was able to accomplish a couple of totally new things.
Because we were in a polar orbit, we saw the poles of Io for the first time and there were volcanoes all over both poles, says Bolton. There were multiple eruptions around the same area over the South Pole which suggested that maybe there was one reservoir that somehow got active, and a few eruptions all happened at the same time, he says.
Io is in orbit around Jupiter, but it's far from a perfectly circular orbit.
On one side of the orbit, it's a little bit closer to Jupiter than on the other side, says Bolton. Jupiter is pulling on the side that's closest to it a little bit more than the side that's far away from it and distorts its spherical shape, he says. So, Io itself is constantly being gravitationally squeezed by Jupiter, causing Io's insides to become very hot and molten and eventually erupt, says Bolton.
Why is studying such a volcanic, eruptive moon like Io important?
Here's this moon that's constantly spewing out volcanoes, says Bolton. By studying Io, he says, we can learn about the volcanoes here on the earth, what's similar, what's different, what are the conditions that cause these things?
On 30 December 2023, the Juno spacecraft, exploring the Jovian system, approached the volcanic moon ... More Io at a distance of just 1500 km (930 miles). A similar encounter is scheduled to take place on 3 February 2024. The probe is monitoring the moon's volcanic activity getty
No spacecraft has ever gone into this hazardous, high-radiation environment; the real danger is near Jupiter where we're in this elliptical, polar orbit, says Bolton. But Juno got within 1500 km above Io's surface, he says.
One reason the mission is a challenge is the nature of the planet Jupiter itself.
Jupiter is more massive than all the other planets in our solar system put together, says Bolton. It's got the strongest magnetic field, largest gravity field and the most ferocious aurorae, including the harshest radiation belts in the entire solar system, he says. Then sitting in the same system is another extreme object, Io, which is the most volcanic body in the solar system, says Bolton. Lava Lakes
We're possibly seeing lakes of lava, possibly that are kind of crusted over, like you see in Hawaii when lava flows get crusted over and look dark, says Bolton. People walk on them, even though it's quite dangerous, because underneath is unbelievably hot lava, he says.
Juno's data suggests that about 10 percent of Io's surface has these remnants of slowly cooling lava just below the surface, says NASA.
As for the overall mission's success?
Even though the mission had some minor hiccups, it's been a grand success.
Once we got there, we saw some symptoms with the rocket motor and its fuel that made us a little nervous about whether we should fire that or not, says Bolton. We were in an orbit that would work; it was just a longer orbit and so we decided not to fire the engine and just stay in that 53-day orbit, he says.
One of Juno's ten active instruments, the Microwave Radiometer (MWR) was specifically invented for the mission.
We're looking at maybe flying one of these instruments right here on Earth to study our own volcanoes, says Bolton. This microwave radiometer was invented for the Juno mission to look below the cloud tops of Jupiter and understand its composition, the dynamics of its storms, he says. But when we pointed at Io, somewhat serendipitously, it allowed us to see into the rock and lava to provide the first real look inside of the moon's subsurface structure, says Bolton.
A further extension notwithstanding, this coming September Juno will end its current extended mission. Launched in 2011, the spacecraft arrived at Jupiter in 2016 and has been scientifically prolific ever since.
The mission represents the best of NASA ingenuity.
One of the greatest things that we've been able to do as humans is figure out how to navigate around the planets and stars, says Bolton. I'm totally amazed that we're able to robotically visit Jupiter, Saturn, Uranus, Neptune, and once there, go into orbit and navigate around their moons, just like driving down to the gas station, he says. In one sense, we're navigating by the stars in the same way we used to do with ancient ships, but now we're navigating between bodies of the solar system, says Bolton. Forbes How Jupiter Helped Spawn Life On Earth By Bruce Dorminey
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time29 minutes ago

  • Yahoo

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet's website at with an archived replay available for 90 days following the live event. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the US. For additional information about Sagimet, please visit Investor Contact:Joyce Allaire LifeSci Advisors JAllaire@ Media Contact:Michael FitzhughLifeSci Advisors mfitzhugh@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center
Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center

Yahoo

timean hour ago

  • Yahoo

Axis Research & Technologies Celebrates 10 Years of Innovation and Sets Its Sights on Vision for Building the First AI-Powered Smart Surgical Center

Future Surgical Center to Be Powered by OMNIMED SmartOR™ Technology, Anchored on a World-Class University Campus and Driven by Axis Research IRVINE, Calif., August 05, 2025--(BUSINESS WIRE)--Axis Research & Technologies, a national leader in bioskills training and medical research environments, proudly marks its 10-year anniversary with a decade of expansion, innovation, and trusted partnerships across the healthcare ecosystem. As it celebrates this milestone, the company unveils its bold next step: a strategic initiative to build the nation's first AI-powered smart surgical center in collaboration with a world-class university. This next-generation facility will unite cadaveric training, surgical simulation, real-time telemetry, and AI-driven insights to support clinical education, medical device innovation, and procedural performance at scale. "We've spent the last 10 years building a trusted network of innovation and excellence," said Nick Moran, Chief Executive Officer of Axis. "As we look to the next decade, our vision is to evolve from best-in-class bioskills labs to the development of intelligent, integrated surgical ecosystems that accelerate discovery and improve outcomes." A National Network Built for Innovation Founded in 2015, Axis operates a network of advanced bioskills labs in Irvine, CA; Columbia (Baltimore), MD; Nashville, TN; and Houston, TX. Each facility is designed to accommodate complex, hands-on surgical training, cadaveric research, device development, and live broadcast education—all supported by Axis's experienced logistics, tissue sourcing, and technical teams. The company's Houston lab, launched in 2025, is strategically located near the Texas Medical Center and continues the Axis tradition of pairing location intelligence with industry demand to better serve surgeons, educators, and medtech leaders. "We've scaled carefully and intentionally to meet the needs of our partners," said Moran. "And now, we're focused on shaping what comes next—where performance, insight, and education converge." OMNIMED and SmartOR™: Powering Data-Driven Surgical Environments Several years ago, Axis became an early adopter and integration partner of OMNIMED™, a medical technology company that had been developing SmartOR™—a first-of-its-kind AI surgical telemetry platform. SmartOR™ captures real-time data across classroom, simulation, and operating room environments, giving educators, researchers, and developers unprecedented insight into tools, workflows, and performance outcomes. OMNIMED's platform is now fully embedded within Axis facilities, enabling predictive modeling, skill gap analysis, protocol validation, and real-time diagnostics. "We're no longer limited to what we can see," said Moran. "Now, we can measure, model, and improve with clarity, speed, and scale." A Strategic Vision for the Future of Surgery As part of its next phase of growth, Axis has announced its intent to align with a premier academic institution to co-develop a 36,000 sq. ft. smart surgical center—designed as a national hub for surgical innovation, clinical research, and medical education. This initiative is a logical and mission-aligned evolution of Axis's capabilities, combining physical infrastructure with proven technology and real-world surgical telemetry. By collaborating with the right university partner, Axis aims to accelerate translational research, bridge academic and industry priorities, and train future generations of surgeons within a connected, data-rich ecosystem. "Axis is committed to working with the ideal institutional partner—one that shares our belief that surgical excellence requires measurable feedback, collaborative design, and intelligent infrastructure," said Jill Goodwin, Chief Operating Officer of Axis. The company will continue developing the center in alignment with its founding principles—creating flexible, scalable environments that connect education, experimentation, and evidence—all in one location. Looking Ahead As Axis enters its second decade, it remains committed to being the platform for surgical progress—delivering training spaces, simulation technologies, and insights that help industry leaders bring better procedures, devices, and outcomes to life. About Axis Research & Technologies Axis operates a national network of advanced bioskills labs that support surgical training, cadaver-based research, and healthcare innovation. With hands-on environments, concierge-level support, and cutting-edge broadcasting and analytics capabilities, Axis serves as a trusted partner to medical device companies, health systems, and academic institutions. Learn more at About OMNIMED OMNIMED is the creator of SmartOR™, an AI-powered surgical telemetry platform that links classroom, simulation, and operating room data into a measurable, intelligent system. Used by educators, clinicians, and developers, SmartOR™ delivers actionable insights to improve training, device testing, and surgical performance. Learn more at View source version on Contacts Media Contact: Kim ShermanOpen Door Consultingkim@

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Yahoo

timean hour ago

  • Yahoo

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ('Jeune'), a wholly owned subsidiary of Krystal Biotech, Inc. ('Krystal') (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS). GAIS assesses the overall aesthetic change in appearance as a result of a treatment. Subjects also reported increased satisfaction with the appearance of wrinkles, as measured by the Subject Satisfaction Questionnaire (SSQ). The SSQ is a tool to gather subject-reported outcomes providing valuable insights on the impact of treatment beyond clinical observations. Topline Efficacy Results A total of 19 subjects were enrolled, 12 were randomized to KB304 and seven to placebo. One subject dropped out before completing KB304 treatments. The remaining 18 subjects were assessed for aesthetic improvement out to three months following KB304 injections in the décolleté. The study investigator and subjects reported a clinically meaningful improvement in wrinkles one, two, and three months after treatment, as assessed by GAIS among KB304-treated subjects. Investigator Reported: At Least One-Point Improvement for Subjects Receiving: Subject Reported: At Least One-Point Improvement for Subjects Receiving: KB304 Placebo KB304 Placebo At Three Months 100% 28.6% 72.7% 14.3% At Two Months 100% 28.6% 90.9% 14.3% At One Month 100% 14.3% 72.7% 14.3% As assessed by SSQ, 81.8% of subjects receiving KB304 reported improved satisfaction with their wrinkles' appearance three months after treatment, compared to 14.3% of subjects receiving placebo. Improvements in subjects receiving KB304 were also seen across multiple additional skin attributes, as assessed by GAIS, including elasticity, crepiness, hydration, and radiance, for which the investigator reported that 100% of subjects demonstrated an improvement of at least 1 point in each of these attributes at one, two, and three months following treatment. 'We are very excited to share today's data update. We are pleased that both the investigator and subjects reported high rates of improvements across a variety of skin attributes when treated with KB304. We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin. KB304 is a truly unique product candidate, which we think will address a massive gap in the market two ways…being the first product candidate to directly address elastin and by doing so in the décolleté where there are no injectable products approved. Consumers are yearning for a solution that delivers natural looking results, and KB304 has the potential to restore the skin to a more youthful appearance,' said Marc Forth, Chief Executive Officer of Jeune. The KB304 safety profile was consistent with prior clinical experience in KB301. Adverse events were mild-to-moderate and mostly reported after the first dose but substantially tapered off with subsequent doses. No severe or drug-related serious adverse events were reported. 'We are extremely excited by the promising data from the Pearl-2 study,' said Suma Krishnan, President of Research & Development at Krystal Biotech. 'We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the body's own skin cells. On the basis of the strong results and broad improvements across multiple skin aesthetic attributes, we will be progressing KB304 into Phase 2 development for the treatment of wrinkles in the décolleté, a priority aesthetic site for which no FDA-approved injectables exist. We plan to prioritize the development of KB304 and will be meeting with the FDA in the coming months to enable initiation of the Phase 2 study.' Jeune has recently completed development and validation of a décolleté-specific photonumeric scale ('JDWS'). Jeune intends to submit the JDWS to the FDA and align on the Phase 2 study protocol in the second half of 2025 with the goal of initiating the Phase 2 study in the first half of 2026. Conference Call and Webcast Jeune and Krystal will host a conference call and webcast today, Thursday, July 24, 2025, at 4:30pm ET, to discuss the results of the PEARL-2 study, the KB304 clinical development program, Jeune's pipeline product candidates, and the strategic vision for Jeune. Investors and the general public can access the live webcast at: For those unable to listen to the live webcast, a replay will be available on the Investor's section of the Krystal website at About KB304 KB304 is an investigational aesthetic therapy employing Krystal's novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the gene encoding COL3 transgene and one copy of the gene encoding elastin to increase their levels in skin and address signs of skin aging associated with damage to the skin's extracellular matrix. KB304 is formulated as a solution for direct intradermal injection to aesthetic priority areas. About the PEARL-2 Study PEARL-2 is a Phase 1 Study of KB304, a replication-defective, non-integrating vector expressing human type III collagen (COL3) and elastin for the treatment of moderate to severe wrinkles of the décolleté. Details of the Phase 1 study can be found at under NCT identifier NCT06724900. About Jeune Aesthetics, Inc. Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company's first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit and follow @KrystalBiotech on LinkedIn and X (formerly Twitter). Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about the clinical utility of KB304; KB304's ability to deliver collagen and elastin to restore the skin naturally to a more youthful appearance and potentially revolutionize the treatment of wrinkles and skin quality; KB304's potential to address a massive gap in the market; Krystal's and Jeune's plans to prioritize the development of KB304 and progress KB304 into a Phase 2 study for the treatment of wrinkles of the décolleté, including timing of meeting with the FDA and the goal of initiating the Phase 2 study in the first half of 2026; and other statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'likely,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: preliminary clinical data from a Phase 1 trial with a small sample size and limited follow-up may not predict results in later-stage studies; uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of KB304, and such other important factors as are set forth under the caption 'Risk Factors' in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's and Jeune's views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's and Jeune's views as of any date subsequent to the date of this press release. CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@ Nishant Saxena Jeune Aesthetics nsaxena@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store